Abstract:Cervical dystonia (CD) is the most frequent focal dystonia. Symptoms often reveal as pain and functional disability. Therefore, it impacts the patients′ life and social quality, leads to the large expectations from patients of which could be cured. This review summarizes recent developments regarding cervical dystonia, with the aim to provide practical recommendations for the treating among clinicians.
[1] Jinnah HA,Teller JK,Galpern WR. Recent developments in dystonia [J]. Curr Opin Neurol,2015,28(4):400-405.
[2] Coelh M,Valadas AF,Mestre T,et al. Pain and quality of life in the treatment of cervical dystonia [J]. Eur Neurol Rev,2009,4(2):74-78.
[3] Jankovic J,Adler CH,Charles D,et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE) [J]. J Neurol Sci,2015,349(1-2):84-93.
[4] Tomic S,Petkovic I,Pucic T,et al. Cervical dystonia and quality of life [J]. Acta Neurol Belg,2016,116(4):589-592.
[5] 马凌燕,万新华.痉挛性斜颈及其诊疗[J].协和医学杂志,2012,3(3):332-336.
[6] Han YI,Stevens AL,Dashtipour K,et al. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia [J]. J Neurol,2016, 263(4):772-780.
[7] Camargo CH,Teive HA. Pain relief in cervical dystonia with botulinum toxin treatment [J]. Toxins (Basel),2015,7(6):2321-2335.
[8] Shanker V,Bressman SB.Diagnosis and Management of Dystonia[J].Continuum (Minneap Minn),2016 22(4 Movement Disorders):1227-1245.
[9] Dobri■i■ V,Kresojevi■ N,?譕arkovi■ M,et al. Phenotype of non-c.907_909delGAG mutations in TOR1A:DYT1 dystonia revisited [J]. Parkinsonism Relat Disord,2015,21(10):1256-1259.
[10] Ledoux MS,Vemula SR,Xiao J,et al. Clinical and genetic features of cervical dystonia in a large multicenter cohort [J]. Neurology Genetics,2016,2(3):e69.
[11] Matsumoto S,Murakami N,Koizumi H,et al. Evaluation of the Edrophonium Challenge Test for Cervical Dystonia [J]. Intern Med,2017,56(18):2415-2421.
[12] Huang L,Chen HX,Ding XD,et al. Efficacy analysis of ultrasound-guided local injection of botulinum toxin type A treatment with orthopedic joint brace in patients with cervical dystonia [J]. Eur Rev Med Pharmacol Sci,2015, 19(11):1989-1993.
[13] Trosch MR. A retrospective,Single-Center comparative cost analysis of Onabotulinumtoxin A and Abobotulinumtoxin A for cervical dystonia treatment [J]. J Manag Care Spec Pha?鄄rm,2015,21(10):854-860.
[14] Nakamura Y. Botulinum toxin for treatment of the focal dystonia [J]. Rinsho Shinkeigaku,2017,57(7):367-372.
[15] Marion,HM. British neurotoxin network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin [J]. Pract Neurol,2016,16(4):288-295.
[16] Jinnah HA,Goodmann E,Rosen AR,et al. Botulinum toxin treatment failures in cervical dystonia:causes,management,and outcomes [J]. J Neurol,2016,263(6):1188-1194.
[17] 王志剑,张达颖,张学学.颈脊神经联合副神经阻滞治疗痉挛性斜颈[J].中国疼痛医学杂志,2015,21(1):67-68.
[18] 陈信康,林少华.选择性周围神经切断和肌切断治疗痉挛性斜颈400例结果[J].中华神经外科杂志,2005,21(1):30-34.
[19] 于炎冰,张黎.改良Foerster-Dandy手术治疗痉挛性斜颈[J].中华神经外科杂志,2005,21(2):88-90.
[20] Thenganatt MA,Jankovic J. Treatment of dystonia [J]. Neu?鄄rotherapeutics,2014,11(1):139-152.
[21] Huh R,Chung M.Electrophysiological interpretations of the clinical response to stimulation parameters of pallidal deep brain stimulation for cervical dystonia [J]. Acta Neu?鄄rochir (Wien),2016,158(10):2029-2038.
[22] Hoffland BS,Kassavetis P,Bologna M,et al. Cerebellum-dependent associative learning deficits in primary dystonia are normalized by rTMS and practice [J]. Eur J Neurosci,2013,38(1):2166-2171.
[23] Pirio Richardson ST,CHEN R. Repetitive transcranial magnetic stimulation in cervical dystonia:effect of site and repetition in a randomized pilot trial [J]. PLoS One,2015,10(4):e0124937.
[24] Allam N,Brasil-Neto JP,Brand?觔o P,et al. Relief of primary cervical dystonia symptoms by low frequency transcranial magnetic stimulation of the premotor cortex:case report [J]. Arq Neuropsiquiatr,2007,65(3A):697-699.
[25] Jinnah HA,Factor SA.Diagnosis and treatment of dystonia [J]. Neurol Clin,2015,33(1):77-100.